Conditions: Non-Small Cell Lung Cancer Carcinoma
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 30
Healthy volunteers: no

Brief summary:
The main purpose of this study of pemetrexed combined with cisplatin used as neoadjuvant chemotherapy (2 or 3 cycles) in participants with operable non-small cell lung cancer (NSCLC) is to look at various genes present in participants' blood and tumor tissue to see if there is any link between the levels or changes in the genes and how participants with lung cancer respond to pemetrexed and cisplatin treatment.

Detailed description:

Arms:
arm 1: Pemetrexed: 500 milligrams per square meter (mg/m\^2) intravenous (IV) every 21 days (q 21 days) for 3 cycles unless disease progression occurs

Cisplatin: 75 mg/m\^2 IV q 21 days for 3 cycles unless disease progression occurs

Interventions: intervention 1: pemetrexed intervention 2: cisplatin intervention 3: Radical Non-Small Cell Lung Cancer (NSCLC) surgery
Intervention descriptions: intervention 1: 500 mg/m\^2 IV q 21 days for 3 cycles unless disease progression occurs intervention 2: 75 mg/m\^2 IV q 21 days for 3 cycles unless disease progression occurs intervention 3: All participants proceeded to surgery within 4-8 weeks from the last dose of pemetrexed.

Protocol document: